European Commission approves Camzyosfor the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy
Bristol Myers Squibb announced that the European Commission (EC) has approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients
Camzyos is the first and only allosteric and reversible inhibitor selective for cardiac myosin approved in all European Union (EU) member states and is the first cardiac myosin inhibitor that targets the underlying pathophysiology of HCM. The EC approval of Camzyos is based upon positive efficacy and safety results from two Phase III trials, EXPLORER-HCM and VALOR-HCM.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.